Small-Molecule Inhibitors of PDK1

被引:106
作者
Peifer, Christian [1 ]
Alessi, Dario R. [1 ]
机构
[1] Univ Dundee, Sch Life Sci, MRC Prot Phosphorylat Unit, MSI WTB Complex, Dundee DD1 5EH, Scotland
关键词
biological activity; inhibitors; PDK1; proliferative diseases; selectivity;
D O I
10.1002/cmdc.200800195
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Signal transduction of many growth factors and oncogenes is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1), a master regulator of a number of downstream signal protein kinose cascades. Hence, PDK1 represents a convergence point for receptor tyrosine kinase and cytokine-medioted pathways for the regulation of vital cell processes such as cell survival and proliferation. Pathological upregulation of PDK1 signalling due to constitutive growth factor receptor activation and/or PTEN (phosphatose and tensin homologue) mutations significantly triggers downstream signalling, e.g. PKB/Akt, which subsequently promote proliferative events such as tumour invosiveness, ongiogenesis, and progression. Consistent with this, a mouse model expressing low levels of PDK1 is protected from tumourigenesis resulting from loss of PTEN. Because more than 50% of all human cancers possess significant overstimulation of the PDK1 signalling pathway, inhibition of this protein kinose by small molecules is predicted to result in effective inhibition of cancer cell proliferation and thus be therapeutically beneficial. Various classes of small-molecule PDK1 inhibitors have been published in patents and papers. Herein we present for the first time a comprehensive collection of small molecules reported to interact with PDK1, and we refer to their biological characterisation in terms of activity and selectivity for PDK1.
引用
收藏
页码:1810 / 1838
页数:29
相关论文
共 85 条
[1]   Microscopic modes and free energies of 3-phosphoinositide-dependent kinase-1 (PDK1) binding with celecoxib and other inhibitors [J].
AbdulHameed, Mohamed Diwan M. ;
Hamza, Adel ;
Zhan, Chang-Guo .
JOURNAL OF PHYSICAL CHEMISTRY B, 2006, 110 (51) :26365-26374
[2]  
[Anonymous], 2006, Patent No. [2006/015124, 2006015124]
[3]  
Arnaiz D., 2006, Patent No. [7105563, US 07105563, 07105563]
[4]  
ARNOLD L, 2007, Patent No. 2007084667
[5]   Toward a pharmacophore for kinase frequent hitters [J].
Aronov, AM ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (23) :5616-5619
[6]   The selectivity of protein kinase inhibitors: a further update [J].
Bain, Jenny ;
Plater, Lorna ;
Elliott, Matt ;
Shpiro, Natalia ;
Hastie, C. James ;
Mclauchlan, Hilary ;
Klevernic, Iva ;
Arthur, J. Simon C. ;
Alessi, Dario R. ;
Cohen, Philip .
BIOCHEMICAL JOURNAL, 2007, 408 :297-315
[7]   A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase [J].
Barlaam, Bernard ;
Ballard, Peter ;
Bradbury, Robert H. ;
Ducray, Richard ;
Germain, Herve ;
Hickinson, D. Mark ;
Hudson, Kevin ;
Kettle, Jason G. ;
Klinowska, Teresa ;
Magnien, Francoise ;
Ogilvie, Donald J. ;
Olivier, Annie ;
Pearson, Stuart E. ;
Scott, James S. ;
Suleman, Abid ;
Trigwell, Cath B. ;
Vautier, Michel ;
Whittaker, Robin D. ;
Wood, Robin .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (02) :674-678
[8]   Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides [J].
Bartlett, S ;
Beddard, GS ;
Jackson, RM ;
Kayser, V ;
Kilner, C ;
Leach, A ;
Nelson, A ;
Oledzki, PR ;
Parker, P ;
Reid, GD ;
Warriner, SL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (33) :11699-11708
[9]   Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/- mice [J].
Bayascas, JR ;
Leslie, NR ;
Parsons, R ;
Fleming, S ;
Alessi, DR .
CURRENT BIOLOGY, 2005, 15 (20) :1839-1846
[10]  
BINCH H, 2003, Patent No. 2003064397